FLT3 and acute myeloid leukemia: To advance our understanding of AML relapse and chemotherapeutic resistance, significant efforts have been made so far and numerous studies have shown that aberrations in several genes, such as MCL-126, TET27, FLT3-ITD28–30, NPM131–33, and CEBPA34–37, are associated with drug resistance in AML treatment.